抗磷脂抗体阳性率及其与新发心血管事件的关联
该研究基于达拉斯心脏研究第2阶段的多民族人群队列,检测2427名参与者的8种抗磷脂抗体(aPL),中位随访8年。任何aPL单次阳性率为14.5%(353/2427),约三分之一为中或高滴度。调整传统危险因素后,aCL IgA(HR 4.92)和aβ2GPI IgA(HR 2.91)独立关联未来ASCVD事件;采用≥40单位阈值时风险进一步升高(aCL IgA HR 9.01,aβ2GPI IgA HR 4.09)。aβ2GPI IgA与胆固醇流出能力负相关(r=-0.055,P=0.009),与氧化LDL正相关(r=0.055,P=0.007),并关联内皮细胞活化表型。作者结论认为单次阳性aCL IgA和aβ2GPI IgA独立关联未来ASCVD事件,需纵向研究进一步探索。
要点
- 在2427名多民族成人中,单次检测任何aPL阳性率为14.5%(353/2427),约三分之一为中或高滴度。
- aCL IgA(HR 4.92;95%CI 1.52-15.98)和aβ2GPI IgA(HR 2.91;95%CI 1.32-6.41)独立关联未来ASCVD事件。
- 采用≥40单位阳性阈值时,aCL IgA的HR为9.01(95%CI 2.73-29.72),aβ2GPI IgA的HR为4.09(95%CI 1.45-11.54)。
- aβ2GPI IgA水平与胆固醇流出能力负相关(r=-0.055;P=0.009),与循环氧化LDL正相关(r=0.055;P=0.007)。
- aβ2GPI IgA阳性血浆关联内皮细胞活化表型,表现为表面E-选择素、细胞间黏附分子-1和血管细胞黏附分子-1表达增加。
适用人群与场景
- 达拉斯心脏研究(DHS)第2阶段的多民族、基于人群的队列参与者,共2427人;平均(SD)年龄50.6(10.3)岁;女性1399人(57.6%);黑人1244人(51.3%)、西班牙裔339人(14.0%)、白人796人(32.8%)。
- 血样采集于2007年至2009年,中位随访8年。
诊断标准与关键阈值
- 采用固相法检测8种aPL:抗心磷脂(aCL)IgG/IgM/IgA、抗β2糖蛋白I(aβ2GPI)IgG/IgM/IgA、抗磷脂酰丝氨酸/凝血酶原(aPS/PT)IgG/IgM。
- 任何aPL阳性定义为单次检测任一aPL阳性;约三分之一阳性者处于中或高滴度。
- 研究还采用至少40单位作为阳性阈值分析风险。
研究设计与关键结果
- 研究类型:基于人群的队列研究(达拉斯心脏研究第2阶段)。样本量2427人,中位随访8年。
- 主要终点为未来ASCVD事件(首次非致死性心肌梗死、首次非致死性卒中、冠状动脉血运重建或心血管原因死亡),采用Cox比例风险模型并调整已知危险因素、药物及多重比较。
- 单次检测任何aPL阳性率为14.5%(353/2427);aCL IgM阳性率最高(156人,6.4%),其次为aPS/PT IgM(88人,3.4%)、aβ2GPI IgM(63人,2.6%)、aβ2GPI IgA(62人,2.5%)。
- aCL IgA(校正HR 4.92;95%CI 1.52-15.98)和aβ2GPI IgA(HR 2.91;95%CI 1.32-6.41)独立关联未来ASCVD事件。
- 采用至少40单位阈值时,aCL IgA的HR为9.01(95%CI 2.73-29.72),aβ2GPI IgA的HR为4.09(95%CI 1.45-11.54)。
- aβ2GPI IgA水平与胆固醇流出能力负相关(r=-0.055;P=0.009),与循环氧化LDL正相关(r=0.055;P=0.007)。
- aβ2GPI IgA阳性血浆关联内皮细胞活化表型,表现为表面E-选择素、细胞间黏附分子-1和血管细胞黏附分子-1表达增加。
证据类型、等级与局限
- 证据类型:基于人群的队列研究。
- 局限:原文未报告局限性;作者在结论中提出需纵向研究连续测量aPL以进一步探索这些发现。
对床旁实践的改变
- 原文未据此给出推荐;作者结论认为单次检测阳性的aCL IgA和aβ2GPI IgA独立关联未来ASCVD事件,需纵向研究进一步探索。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The prevalence of antiphospholipid antibodies (aPL) and their association with future atherosclerotic cardiovascular disease (ASCVD) risk has yet to be thoroughly investigated.
OBJECTIVE: To determine the association between measurements of aPL at a single time point and ASCVD risk in a diverse population.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study measured 8 aPL (anticardiolipin [aCL] IgG/IgM/IgA, anti-beta-2 glycoprotein I [aβ2GPI] IgG/IgM/IgA, and antiphosphatidylserine/prothrombin [aPS/PT] IgG/IgM) by solid-phase assays in plasma from participants of the Dallas Heart Study (DHS) phase 2, a multiethnic, population-based cohort study. Blood samples were collected between 2007 and 2009. The median follow-up was 8 years. Statistical analysis was performed from April 2022 to January 2023.
MAIN OUTCOMES AND MEASURES: Associations of aPL with future ASCVD events (defined as first nonfatal myocardial infarction, first nonfatal stroke, coronary revascularization, or death from cardiovascular cause) were assessed by Cox proportional hazards models, adjusting for known risk factors, medications, and multiple comparisons.
RESULTS: Among the 2427 participants (mean [SD] age, 50.6 [10.3] years; 1399 [57.6%] female; 1244 [51.3%] Black, 339 [14.0%] Hispanic, and 796 [32.8%] White), the prevalence of any positive aPL tested at a single time point was 14.5% (353 of 2427), with approximately one-third of those detected at a moderate or high titer; aCL IgM had the highest prevalence (156 individuals [6.4%]), followed by aPS/PT IgM (88 [3.4%]), aβ2GPI IgM (63 [2.6%]), and aβ2GPI IgA (62 [2.5%]). The IgA of aCL (adjusted hazard ratio [HR], 4.92; 95% CI, 1.52-15.98) and aβ2GPI (HR, 2.91; 95% CI, 1.32-6.41) were independently associated with future ASCVD events. The risk further increased when applying a positivity threshold of at least 40 units (aCL IgA: HR, 9.01 [95% CI, 2.73-29.72]; aβ2GPI IgA: HR, 4.09 [95% CI, 1.45-11.54]). Levels of aβ2GPI IgA negatively correlated with cholesterol efflux capacity (r = -0.055; P = .009) and positively correlated with circulating oxidized LDL (r = 0.055; P = .007). aβ2GPI IgA-positive plasma was associated with an activated endothelial cell phenotype as evidenced by increased surface expression of surface E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1.
CONCLUSIONS AND RELEVANCE: In this population-based cohort study, aPL detectable by solid-phase assays were present in a substantial proportion of adults; positive aCL IgA and aβ2GPI IgA at a single time point were independently associated with future ASCVD events. Longitudinal studies with serial aPL measurements are needed to further explore these findings.
参考来源
- Zuo Y, Navaz S, Liang W, et al. Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events. JAMA Netw Open. 2023. PMID: 37014642. doi:10.1001/jamanetworkopen.2023.6530
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。